Anzeige
Meldung des Tages: Straße von Hormus wieder im Fokus - und warum Permian-Barrels jetzt noch wertvoller sind

Regenxbio News

Aktie
WKN:  A140E0 ISIN:  US75901B1070 US-Symbol:  RGNX Branche:  Biotechnologie Land:  USA
8,126 €
+0,038 €
+0,47%
09:43:32 Uhr
Depot/Watchlist
Marktkapitalisierung *
602,52 Mio. €
Streubesitz
8,44%
KGV
-1,73
Index-Zuordnung
-

Regenxbio News

19.02.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX PR ...
19.02.26 - PR Newswire
RGNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
RGNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 PR Newswire
19.02.26 - PR Newswire
The Gross Law Firm Notifies REGENXBIO Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RGNX
The Gross Law Firm Notifies REGENXBIO Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RGNX PR Newswire
18.02.26 - PR Newswire
RGNX Stockholder Alert: Robbins LLP Remind Investors of the Class Action Lawsuit Against REGENXBIO, Inc.
RGNX Stockholder Alert: Robbins LLP Remind Investors of the Class Action Lawsuit Against REGENXBIO, Inc. PR Newswire
18.02.26 - PR Newswire
Shareholders that lost money on REGENXBIO Inc. (RGNX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Shareholders that lost money on REGENXBIO Inc. (RGNX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More PR Newswire
16.02.26 - PR Newswire
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit PR Newswire
12.02.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX PR Newswire
09.02.26 - PR Newswire
REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II
REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II PR Newswire
29.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX PR Newswire
29.01.26 - PR Newswire
Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action
Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action PR Newswire
28.01.26 - PR Newswire
REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs PR Newswire
11.01.26 - PR Newswire
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program
REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program PR Newswire
18.12.25 - PR Newswire
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
25.11.25 - PR Newswire
REGENXBIO to Participate in Upcoming Investor Conference
REGENXBIO to Participate in Upcoming Investor Conference PR Newswire
06.11.25 - PR Newswire
REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights
REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights PR Newswire
30.10.25 - PR Newswire
REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program
REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program PR Newswire
29.10.25 - PR Newswire
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights PR Newswire
15.10.25 - PR Newswire
REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire
09.10.25 - PR Newswire
REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting
REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting PR Newswire
06.10.25 - PR Newswire
REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD
REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD PR Newswire

Newssuche

Videos

newspaper
19.04.26
CRASH-​ALARM?! Steht die nächste Baisse unmittelbar bevor?
Mehr »